Recent Updates
Recently added Catalysts
EVO Positive Sentiment Score: 80/100

Just - Evotec Biologics enters strategic biosimilars partnership with Sandoz Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Ev

Tuesday, May 9, 2023 1 min read
Key Takeaway: Evotec SE has announced a strategic partnership involving its subsidiary, Just - Evotec Biologics, and Sandoz for the development and manufacturing of biosimilars. This long-term collaboration includes a potential in-licensing of Evotec's proprietary J.DESIGN technology. Evotec is set to receive multi-million dollar upfront payments, with further financial incentives tied to successful development and commercialization progress. The partnership aims to enhance production capabilities through a new facility that Sandoz will build and operate.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic partnership with Sandoz enhances Evotec's biosimilars portfolio.
  • Potential for significant future revenue through successful development payments.
  • Access to Sandoz's capabilities for manufacturing biosimilars.
  • In-licensing of proprietary technology may strengthen competitive positioning.

Full Press Release Details

Just - Evotec Biologics enters strategic biosimilars partnership with Sandoz
Hamburg, Germany, - Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimilars.
The partnership includes an option for the non-exclusive in-licensing of Just - Evotec Biologics' proprietary J.DESIGN technology by Sandoz to build a state-of-the-art, S.POD' facility fully owned by Sandoz in the latter part of this decade.
Just - Evotec Biologics will receive a double-digit-million upfront and future payments of US$ 640 m dependent on successful development progress as well as additional undisclosed payments dependent on progress into commercial manufacturing and exercise of the licensing option.
- End of the ad hoc release -
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, Email: werner.lanthaler@evotec.com

Frequently Asked Questions

What do Evotec and Sandoz's partnership focus on?

The partnership centers on developing and manufacturing multiple biosimilars.

What technology will Sandoz in-license from Evotec?

Sandoz has the option to in-license Evotec's proprietary J.DESIGN technology.

What financial arrangements are included in this partnership?

Evotec will receive an upfront payment and up to $640 million based on milestones.

When will the S.POD facility be established?

The state-of-the-art S.POD facility is planned for the latter part of this decade.

Who can be contacted for more information on this partnership?

Dr. Werner Lanthaler, CEO of Evotec SE, is the contact for inquiries.

Tags: EVO Viatris Investor Conferences Healthcare Evotec Sandoz biosimilars partnership J.DESIGN
Last updated: May 9, 2023